Study of Glutathione-s-transferase and Reduced Glutathione Receiving Chemotherapy

Abstract

Cervical cancer is the third most prevalent cancer in women worldwide, and the fourth leading cause of death from cancer in women. Recent advances, such as the availability of broad scale genome data, articulated gene tag (EST) data bases, innovative sequence alignment techniques, and X-ray crystallography determination of three-dimensional structures, have significantly expanded our understanding of structure–function relationships in this important enzyme superfamily. Total 36 histologically confirmed patients, locally advanced FIGO stage  IIB–IIIB cervical cancer were enrolled. Based on the findings of our research, it can be concluded that improvements in GSH concentration during the treatment of locally advanced cervical cancer can have a major impact on the treatment response. In comparison to the lack of concentration changes in the blood serum of patients who have had no reaction to medication or who have had a reported relapse following treatment, GSH tends to be an effective   indicator.